Salem Investment Counselors Inc. Lowers Stock Position in Boston Scientific Corporation $BSX

Salem Investment Counselors Inc. reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 6.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 188,810 shares of the medical equipment provider’s stock after selling 12,722 shares during the period. Salem Investment Counselors Inc.’s holdings in Boston Scientific were worth $8,058,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BSX. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific during the fourth quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd purchased a new position in Boston Scientific in the first quarter worth $28,000. Finally, Sfam LLC bought a new position in Boston Scientific in the 4th quarter valued at $29,000. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. TD Cowen decreased their price objective on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Truist Financial dropped their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research report on Friday, June 12th. BTIG Research lowered their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 29th. Finally, Wells Fargo & Company dropped their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Price Performance

Boston Scientific stock opened at $51.40 on Thursday. The firm has a market capitalization of $74.49 billion, a P/E ratio of 20.81, a PEG ratio of 1.12 and a beta of 0.56. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The business has a fifty day moving average price of $45.94 and a 200-day moving average price of $59.69.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has authorized a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 204,322 shares of company stock valued at $9,939,221. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.